SCOPE: Observational Study of the Consequences of the Protease Inhibitor Era

Description

SCOPE is an observational, prospective study of HIV-1 infected volunteers designed to provide a specimen bank of samples with carefully characterized clinical data. SCOPE specimens will be used to examine multiple questions involving virologic, immunologic, and host factors involved in HIV-1 infection, progression, non-progression, response to treatment, control of HIV-1 virus, and evolution of drug resistance.

Conditions

HIV Infections

Talk to us

Study Overview

On this page

Study Details

Study overview

SCOPE is an observational, prospective study of HIV-1 infected volunteers designed to provide a specimen bank of samples with carefully characterized clinical data. SCOPE specimens will be used to examine multiple questions involving virologic, immunologic, and host factors involved in HIV-1 infection, progression, non-progression, response to treatment, control of HIV-1 virus, and evolution of drug resistance.

SCOPE: Observational Study of the Consequences of the Protease Inhibitor Era

SCOPE: Observational Study of the Consequences of the Protease Inhibitor Era

Condition
HIV Infections
Intervention / Treatment

-

Contacts and Locations

San Francisco

San Francisco General Hospital, San Francisco, California, United States, 94110

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

For general information about clinical research, read Learn About Studies.

Eligibility Criteria

  • 1. Documented HIV viral load less than 2000 copies/ml WITHOUT taking antiretroviral therapy
  • 2. Undetectable HIV viral load with CD4 T-cells consistently less than 350 for the last 12 months while taking a stable antiretroviral regimen.
  • 3. Antiretroviral naive and planning to start an antiretroviral regimen - any CD4 or HIV viral load acceptable.
  • 4. Long-term Non Progressors: HIV-positive at least 10 years, no antiretroviral therapy for the past 10 years or more, any viral load acceptable, CD4-T cell count always above 500.
  • 1. Active opportunistic infection or systemic treatment for opportunistic infection within the last 4 months (oral candidiasis acceptable)
  • 2. Active treatment for cancer
  • 3. Active treatment for hepatitis C requiring interferon based therapy
  • 4. Immunosuppressive therapy taken within the last 4 months

Ages Eligible for Study

18 Years to

Sexes Eligible for Study

ALL

Accepts Healthy Volunteers

No

Collaborators and Investigators

University of California, San Francisco,

Steven G. Deeks, M.D., PRINCIPAL_INVESTIGATOR, University of California, San Francisco

Study Record Dates

2033-12